期刊
JOURNAL OF MOLECULAR NEUROSCIENCE
卷 58, 期 1, 页码 59-65出版社
SPRINGERNATURE
DOI: 10.1007/s12031-015-0651-1
关键词
HIV-associated neurocognitive disorder (HAND); AIDS; NMDA-type glutamate receptors; GluN3A; gp120; Memantine; NitroMemantine
资金
- NIH [P01 HD29587, P30 NS076411, R21 NS083415, R01 EY09024]
- Brain & Behavior Research Foundation
HIV-associated neurocognitive disorder (HAND) consists of motor and cognitive dysfunction in a relatively large percentage of patients with AIDS. Prior work has suggested that at least part of the neuronal and synaptic damage observed in HAND may occur due to excessive stimulation of NMDA-type glutamate receptors (NMDARs). Here, we compared pharmacological and genetic manipulation of NMDAR activity using an improved derivative of the NMDAR antagonist memantine, termed NitroMemantine, and the modulatory NMDAR subunit GluN3A in the HIV/gp120 transgenic (tg) mouse model of HAND. Interestingly, we found that while both NitroMemantine and GluN3A have been shown to inhibit NMDAR activity, NitroMemantine protected synapses in gp120-tg mice, but overexpression of GluN3A augmented the damage. Given recent findings in the field, one explanation for this apparently paradoxical result is the location of the NMDARs primarily affected, with NitroMemantine inhibiting predominantly extrasynaptic pathologically activated NMDARs, but GluN3A disrupting normal NMDAR-mediated neuroprotective activity via inhibition of synaptic NMDARs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据